UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): 05/04/2011
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15313
DE | | 13-3033811 |
(State or other jurisdiction of | | (IRS Employer |
incorporation) | | Identification No.) |
One Tower Center
East Brunswick, NJ 08816
(Address of principal executive offices, including zip code)
732-418-9300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On May 5, 2011, Savient Pharmaceuticals, Inc. (the "Registrant") announced its financial results for the quarter ended March 31, 2011. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.In addition, also on May 5, 2011, the Registrant held a publicly available live webcast discussion of its financial results for the quarter ended March 31, 2011. The transcript of the May 5, 2011 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
Item 8.01. Other Events
On May 4, 2011, the Registrant announced that it had, through its wholly owned subsidiary, Savient Pharma Ireland Limited, delivered via courier to the European Medicines Agency and the assigned co-rapporteurs, the Marketing Authorization Application for KRYSTEXXA(R) (pegloticase). The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.3 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
See Exhibit Index attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | Savient Pharmaceuticals, Inc. |
| |
| |
| Date: May 09, 2011 | | | | By: | | /s/ Philip K. Yachmetz
|
| | | | | | | | | Philip K. Yachmetz |
| | | | | | | | | SVP & General Counsel |
| |
| |
EXHIBIT INDEX
Exhibit No.
| | Description
|
| EX-99.1 | | Press Release dated May 5, 2011 |
| EX-99.2 | | Transcript dated May 5, 2011 |
| EX-99.3 | | Press Release dated May 4, 2011 |
